TScan adds another $100M to the pot as it plots new TCR cancer trials

Retrieved on: 2021-01-25 13:18:45

Tags for this article:

Click the tags to see associated articles and topics

TScan adds another $100M to the pot as it plots new TCR cancer trials. View article details on hiswai:

Excerpt

Existing investors including founding investor Longwood Fund, 6 Dimensions Capital, Bessemer Venture Partners, GV, Novartis Venture Fund and ...

Article found on: www.fiercebiotech.com